We present a case of posterior reversible encephalopathy syndrome with severe clinical manifestation. Apart from initial aphasia, hemiparesis, and a generalized seizure, the patient had a prolonged loss of consciousness. Although blood pressure was normalized, the clinical status deteriorated continuously. After adding steroids to the therapy, the patient recovered rapidly, suggesting that this could have been a useful therapeutic approach. Even the vasogenic edema in the cerebral magnetic resonance imaging disappeared shortly within 6 days.

Posterior reversible encephalopathy syndrome (PRES) is a severe, life-threatening neurological disorder clinically presenting with various symptoms such as headache, visual disturbances, and epileptic seizures [1]. PRES is characterized by usually bilateral cerebral vasogenic edema in computed tomography (CT) and magnetic resonance imaging (MRI) scans and occurs most commonly in patients with uncontrolled hypertensive blood pressure [2-4]. Impairment of cerebral blood flow autoregulation with consecutive local hyperperfusion is supposed to be the underlying pathomechanism [5]. Different predisposing factors such as endothelial dysfunction in the context of autoimmune diseases, sepsis, preeclampsia/eclampsia, renal failure, and toxic agents like chemotherapeutic or immunosuppressive drugs are described in the literature [6-9]. Therapeutic measurements include rigorous lowering of arterial blood pressure and treatment of complications [10, 11]. In this context we describe a patient who presented to our department with severe PRES treated with high doses of corticosteroids in addition to the arterial blood pressure lowering, resulting in rapid clinical recovery and finally complete resolution of the brain lesions in MRI.

A 77-year-old patient with acute symptoms of left-sided middle cerebral artery stroke was referred to our department. Neurological examination revealed Broca’s aphasia and right-sided hemiparesis. The initial blood pressure was 200/110 mm Hg. Cranial CT with CT angiography ruled out acute cerebral infarction as well as a cerebral hemorrhage; no arterial vessel occlusions were identified. According to current recommendations, intravenous thrombolysis with recombinant tissue-type plasminogen activator was administered. Lowering of blood pressure was immediately and successfully initiated with urapidil under constant monitoring. Nevertheless, the patient suffered a generalized epileptic seizure later on, which is why an anticonvulsive medication (with levetiracetam intravenously) was initiated. Subsequently the patient underwent cerebral MRI, revealing symmetric bilateral white matter lesions with cortical involvement in the parieto-occipital lobe and the cerebellum (Fig. 1). Diffusion-weighted MRI sequences remained unremarkable, without findings indicating acute brain ischemia in the scope of brain infarction.

Fig. 1.

a, c Vasogenic edema in the parieto-occipital lobe and cerebellum in axial FLAIR magnetic resonance images. b, d Completely regressive vasogenic edema in axial FLAIR magnetic resonance imaging after consequent blood pressure lowering and corticosteroid treatment.

Fig. 1.

a, c Vasogenic edema in the parieto-occipital lobe and cerebellum in axial FLAIR magnetic resonance images. b, d Completely regressive vasogenic edema in axial FLAIR magnetic resonance imaging after consequent blood pressure lowering and corticosteroid treatment.

Close modal

Even though blood pressure was normalized in a timely manner and thrombolysis was applied, the patient’s clinical status deteriorated continuously, resulting in severely impaired consciousness. In summary of the findings (clinical presentation, MRI, mild pleocytosis in cerebrospinal fluid), two differential diagnoses were considered: PRES or encephalitis. Hence, the current medication was complemented by an antiviral medication (acyclovir intravenously) and a 3-day corticosteroid treatment (1,000 mg methylprednisolone per day). Viral encephalitis caused by herpes or varicella zoster virus could not be proven, so as a logical consequence the antiviral therapy was stopped immediately. The antiepileptic medication as well as the antihypertensive therapy were continued. By that time, blood pressure remained stable in a normal range. Status epilepticus was ruled out by serial electroencephalographies. After initiation of the steroid therapy the patient’s clinical status improved rapidly. After 2 days of therapy the patient completely regained consciousness. Only a mild paresis of the right arm could be noted as a residuum. After 6 days follow-up cerebral MRI demonstrated no pathological findings (Fig. 1), and no neurological deficit could be identified.

We made the final diagnosis of PRES. Retrospectively, we interpreted the brain lesions detected in the cerebral MRI as vasogenic edema as a cause of acute PRES. These lesions resolved in line with a notable clinical improvement, potentially augmented by the intravenous therapy with steroids, which were administrated due to considerations of differential diagnoses. The patient’s medical history revealed rheumatoid arthritis treated with methotrexate as a preconditioning factor for PRES.

We report the case of a patient with PRES presenting with severe clinical manifestation: aphasia, hemiparesis, generalized seizure, and prolonged loss of consciousness. Although blood pressure was normalized, the clinical status deteriorated continuously. After adding steroids to the therapy, the patient recovered rapidly, suggesting that this could have been a useful therapeutic measure. Even the vasogenic edema in the cerebral MRI disappeared within few days.

PRES usually presents with symptoms such as headaches, seizures, and focal neurological deficits that recede on average 8 days after the onset of symptoms; in 10–20% of patients residual neurological deficits persist [5, 12, 13]. Our patient experienced obviously a rare form of PRES with severe clinical presentation; in 1 out of 10 patients a persisting loss of consciousness leads to the necessity for oral intubation and artificial ventilation [13]. Severe forms of PRES are associated with a higher mortality and are less reversible [12, 14, 15]. After 3 months half of the patients with severe PRES still have a functional impairment [2]. In our case, further complications could be avoided as the clinical status improved, underlining the hypothesis of a positive effect of high-dose steroids in the acute phase of the disease.

Considering the efficiently normalized blood pressure in our patient in presence of his severe clinical condition before starting steroids, the effect on the positive outcome due to the latter seems likely. The short-term recovery in our patient within less than 2 days – from prolonged loss of consciousness to only mild paresis of the right arm – also suggests that steroid therapy potentially boosted the recovery process.

In line with the clinical improvement the structural changes depicted in the brain imaging disappeared after 1 week. In the follow-up examination no pathological findings suggesting a vasogenic edema could be identified. Reviewing the literature, 1 month after the index event, more than half of the patients present with pathological findings related to PRES in the cerebral MRI [12]. In severe cases of PRES residual lesions might occur even more often [16]. In this context the complete resolution of brain lesions after 1 week in our patient also supports the hypothesis that the administration of steroids significantly contributed to this development.

Considering the potential mechanism in PRES, with disturbance of cerebral blood flow and consecutive development of a vasogenic edema, it seems logical that therapeutic measures are aimed at the treatment of this edema. It is well known that steroids have a favorable influence regarding the outcome in different brain disorders associated with secondary edema [17-21]. Therefore and based on pathophysiological considerations, a positive treatment effect of steroids for reducing edema caused by PRES appears likely. Our case report might support this hypothesis. However, systematic investigations are needed to verify the effect of steroids in acute PRES.

The patient gave informed consent for publication of this case report.

The authors declare that they have no competing interests.

1.
Hinchey
J
,
Chaves
C
,
Appignani
B
,
Breen
J
,
Pao
L
,
Wang
A
, et al.
A reversible posterior leukoencephalopathy syndrome
.
N Engl J Med
.
1996
Feb
;
334
(
8
):
494
500
.
[PubMed]
0028-4793
2.
Legriel
S
,
Schraub
O
,
Azoulay
E
,
Hantson
P
,
Magalhaes
E
,
Coquet
I
, et al.;
Critically III Posterior Reversible Encephalopathy Syndrome Study Group (CYPRESS)
.
Determinants of recovery from severe posterior reversible encephalopathy syndrome
.
PLoS One
.
2012
;
7
(
9
):
e44534
.
[PubMed]
1932-6203
3.
McKinney
AM
,
Short
J
,
Truwit
CL
,
McKinney
ZJ
,
Kozak
OS
,
SantaCruz
KS
, et al.
Posterior reversible encephalopathy syndrome: incidence of atypical regions of involvement and imaging findings
.
AJR Am J Roentgenol
.
2007
Oct
;
189
(
4
):
904
12
.
[PubMed]
0361-803X
4.
Stevens
CJ
,
Heran
MK
.
The many faces of posterior reversible encephalopathy syndrome
.
Br J Radiol
.
2012
Dec
;
85
(
1020
):
1566
75
.
[PubMed]
0007-1285
5.
Fugate
JE
,
Rabinstein
AA
.
Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions
.
Lancet Neurol
.
2015
Sep
;
14
(
9
):
914
25
.
[PubMed]
1474-4422
6.
Bartynski
WS
.
Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema
.
AJNR Am J Neuroradiol
.
2008
Jun
;
29
(
6
):
1043
9
.
[PubMed]
0195-6108
7.
Fischer
M
,
Schmutzhard
E
.
Posterior reversible encephalopathy syndrome
.
J Neurol
.
2017
Aug
;
264
(
8
):
1608
16
.
[PubMed]
0340-5354
8.
Fugate
JE
,
Claassen
DO
,
Cloft
HJ
,
Kallmes
DF
,
Kozak
OS
,
Rabinstein
AA
.
Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings
.
Mayo Clin Proc
.
2010
May
;
85
(
5
):
427
32
.
[PubMed]
0025-6196
9.
Granata
G
,
Greco
A
,
Iannella
G
,
Granata
M
,
Manno
A
,
Savastano
E
, et al.
Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches
.
Autoimmun Rev
.
2015
Sep
;
14
(
9
):
830
6
.
[PubMed]
1568-9972
10.
Hobson
EV
,
Craven
I
,
Blank
SC
.
Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness
.
Perit Dial Int
.
2012
Nov-Dec
;
32
(
6
):
590
4
.
[PubMed]
0896-8608
11.
Roth
C
,
Ferbert
A
.
The posterior reversible encephalopathy syndrome: what’s certain, what’s new?
Pract Neurol
.
2011
Jun
;
11
(
3
):
136
44
.
[PubMed]
1474-7758
12.
Burnett
MM
,
Hess
CP
,
Roberts
JP
,
Bass
NM
,
Douglas
VC
,
Josephson
SA
.
Presentation of reversible posterior leukoencephalopathy syndrome in patients on calcineurin inhibitors
.
Clin Neurol Neurosurg
.
2010
Dec
;
112
(
10
):
886
91
.
[PubMed]
0303-8467
13.
Tlemsani
C
,
Mir
O
,
Boudou-Rouquette
P
,
Huillard
O
,
Maley
K
,
Ropert
S
, et al.
Posterior reversible encephalopathy syndrome induced by anti-VEGF agents
.
Target Oncol
.
2011
Dec
;
6
(
4
):
253
8
.
[PubMed]
1776-2596
14.
Lee
VH
,
Wijdicks
EF
,
Manno
EM
,
Rabinstein
AA
.
Clinical spectrum of reversible posterior leukoencephalopathy syndrome
.
Arch Neurol
.
2008
Feb
;
65
(
2
):
205
10
.
[PubMed]
0003-9942
15.
Lin
JT
,
Wang
SJ
,
Fuh
JL
,
Hsiao
LT
,
Lirng
JF
,
Chen
PM
.
Prolonged reversible vasospasm in cyclosporin A-induced encephalopathy
.
AJNR Am J Neuroradiol
.
2003
Jan
;
24
(
1
):
102
4
.
[PubMed]
0195-6108
16.
Kastrup
O
,
Schlamann
M
,
Moenninghoff
C
,
Forsting
M
,
Goericke
S
.
Posterior Reversible Encephalopathy Syndrome: The Spectrum of MR Imaging Patterns
.
Clin Neuroradiol
.
2015
Jun
;
25
(
2
):
161
71
.
[PubMed]
1869-1439
17.
Esquenazi
Y
,
Lo
VP
,
Lee
K
.
Critical Care Management of Cerebral Edema in Brain Tumors
.
J Intensive Care Med
.
2017
Jan
;
32
(
1
):
15
24
.
[PubMed]
0885-0666
18.
Kaal
EC
,
Vecht
CJ
.
The management of brain edema in brain tumors
.
Curr Opin Oncol
.
2004
Nov
;
16
(
6
):
593
600
.
[PubMed]
1040-8746
19.
Miller
JD
,
Leech
P
.
Effects of mannitol and steroid therapy on intracranial volume-pressure relationships in patients
.
J Neurosurg
.
1975
Mar
;
42
(
3
):
274
81
.
[PubMed]
0022-3085
20.
Ramos-Estebanez
C
,
Lizarraga
KJ
,
Merenda
A
.
A systematic review on the role of adjunctive corticosteroids in herpes simplex virus encephalitis: is timing critical for safety and efficacy?
Antivir Ther
.
2014
;
19
(
2
):
133
9
.
[PubMed]
1359-6535
21.
Ryken
TC
,
McDermott
M
,
Robinson
PD
,
Ammirati
M
,
Andrews
DW
,
Asher
AL
, et al.
The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline
.
J Neurooncol
.
2010
Jan
;
96
(
1
):
103
14
.
[PubMed]
0167-594X
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.